50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Poverty and inflation: Egypt's economy hit by global turmoil
CVE:DMT

Small Pharma - DMT Stock Forecast, Price & News

C$0.16
-0.01 (-3.03%)
(As of 09/23/2022 12:57 PM ET)
Add
Compare
Today's Range
C$0.16
C$0.17
50-Day Range
C$0.10
C$0.39
52-Week Range
C$0.09
C$0.70
Volume
25,189 shs
Average Volume
130,946 shs
Market Capitalization
C$51.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$1.00

Small Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
525.0% Upside
C$1.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$26,310 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

About Small Pharma

Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.

Receive DMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter.

DMT Stock News Headlines

Small Pharma Inc (DMT)
3A Deeper Look At DMT Trials & Studies
A Deeper Look At DMT Trials & Studies
Small Pharma Inc.: World's First Clinical...
See More Headlines
Receive DMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter.

DMT Company Calendar

Last Earnings
7/15/2022
Today
9/25/2022
Next Earnings (Estimated)
11/07/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$1.00
High Stock Price Forecast
C$1.00
Low Stock Price Forecast
C$1.00
Forecasted Upside/Downside
+525.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$-1,162.00
Price / Sales
-44,406.20
Cash Flow
C$0.09 per share
Book Value
C$0.10 per share

Miscellaneous

Free Float
N/A
Market Cap
C$51.60 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. George Tziras
    CEO & Non-Independent Director
  • Mr. Peter David Rands
    Chief Innovation & Intellectual Property Officer, Founder and Director
  • Mr. David Steel
    Chief Financial Officer
  • Dr. Carol Routledge
    Chief Scientific & Medical Officer
  • Ms. Marie Claire Layzell
    Chief Manufacturing & Devel. Officer & Director
  • Dr. Alastair James Riddell M.D. (Age 73)
    M.Sc., MBChB, MFPM, MRCGP, MSc, Ph.D., Chief Operating Officer
  • Ms. Emma Hodge
    Head of Intellectual Property
  • Mr. Richard M. Kimel HBA (Age 55)
    LLB, Corp. Sec.
  • Ms. Sarah Hamilton
    Group Financial Controller
  • Mr. Jim Rennie
    Director of Devel. and Member of Scientific & Advisory Board













DMT Stock - Frequently Asked Questions

Should I buy or sell Small Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Small Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DMT shares.
View DMT analyst ratings
or view top-rated stocks.

What is Small Pharma's stock price forecast for 2022?

2 Wall Street research analysts have issued 1-year target prices for Small Pharma's shares. Their DMT share price forecasts range from C$1.00 to C$1.00. On average, they predict the company's share price to reach C$1.00 in the next twelve months. This suggests a possible upside of 525.0% from the stock's current price.
View analysts price targets for DMT
or view top-rated stocks among Wall Street analysts.

How have DMT shares performed in 2022?

Small Pharma's stock was trading at C$0.32 at the beginning of 2022. Since then, DMT stock has decreased by 50.0% and is now trading at C$0.16.
View the best growth stocks for 2022 here
.

When is Small Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our DMT earnings forecast
.

How were Small Pharma's earnings last quarter?

Small Pharma Inc. (CVE:DMT) released its earnings results on Friday, July, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02).

What is Small Pharma's stock symbol?

Small Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMT."

How do I buy shares of Small Pharma?

Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Small Pharma's stock price today?

One share of DMT stock can currently be purchased for approximately C$0.16.

How much money does Small Pharma make?

Small Pharma (CVE:DMT) has a market capitalization of C$51.60 million and generates C$-1,162.00 in revenue each year.

How can I contact Small Pharma?

The official website for the company is www.smallpharma.co.uk. The company can be reached via phone at 44 78 1212 1944.

This page (CVE:DMT) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.